LADENBURG THALM/SH SH Initiates Coverage on Inhibikase Therapeutics

Analysts set a "buy" rating and $4.00 target price for the biopharmaceutical company.

Published on Mar. 4, 2026

Got story updates? Submit your updates here. ›

LADENBURG THALM/SH SH has initiated coverage on shares of Inhibikase Therapeutics (NYSE:IKT), a clinical-stage biopharmaceutical company focused on rare neurodegenerative diseases. The firm set a "buy" rating and a $4.00 price target for the company, suggesting a potential upside of over 100% from the stock's current trading price.

Why it matters

Inhibikase Therapeutics is a relatively young and lesser-known biopharmaceutical company, so this new coverage from a respected investment firm could help raise awareness and potentially drive investor interest in the stock. The positive rating and price target also signal that analysts see significant upside potential in the company's drug development pipeline and future prospects.

The details

LADENBURG THALM/SH SH's analysts cited Inhibikase Therapeutics' lead investigational candidate, IKT-148009, a brain-penetrant inhibitor of PDK1 and ABL kinases, as a key factor behind the firm's bullish outlook. Several other analysts have also issued "buy" ratings on Inhibikase, with price targets ranging from $4.00 to $8.00 per share.

  • Analysts at LADENBURG THALM/SH SH initiated coverage on Inhibikase Therapeutics on Wednesday, March 4, 2026.

The players

Inhibikase Therapeutics

A clinical-stage biopharmaceutical company focused on developing small-molecule kinase inhibitors for rare neurodegenerative diseases.

LADENBURG THALM/SH SH

An investment firm that has initiated coverage on Inhibikase Therapeutics with a "buy" rating and $4.00 price target.

Got photos? Submit your photos here. ›

The takeaway

This new coverage from LADENBURG THALM/SH SH could help raise the profile of Inhibikase Therapeutics and its drug development pipeline, potentially attracting more investor interest in the stock. The positive rating and price target suggest analysts see significant upside potential in the company's future prospects.